Published in Eur Arch Psychiatry Clin Neurosci on November 04, 2005
Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry (2014) 4.41
Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2011) 1.41
Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2010) 1.18
The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs (2014) 1.18
A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol (2007) 1.10
An industry perspective on the NIMH consensus statement on negative symptoms. Schizophr Bull (2006) 0.98
Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation. Eur Arch Psychiatry Clin Neurosci (2006) 0.90
Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatr Dis Treat (2007) 0.87
Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci (2007) 0.84
Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: a randomized clinical trial. Int Arch Med (2013) 0.78
Modulation of human motor cortex excitability by quetiapine. Psychopharmacology (Berl) (2007) 0.77
Predictive eye and hand movements are differentially affected by schizophrenia. Eur Arch Psychiatry Clin Neurosci (2007) 0.76
Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia. Case Rep Psychiatry (2016) 0.75
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl (1970) 10.05
Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry (1999) 8.04
The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl (1989) 4.53
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res (1999) 4.13
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med (1993) 3.76
Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull (1997) 2.90
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry (2003) 2.48
Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry (1997) 1.89
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology (1999) 1.45
Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia. Biol Psychiatry (1990) 1.41
Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry (1994) 1.32
Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs (2004) 1.03
Adverse events related to olanzapine. J Clin Psychiatry (2000) 0.93
A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol (2000) 0.89
Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol (1998) 0.87
Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull (2002) 0.86
Quetiapine in schizophrenia: onset of action within the first week of treatment. Curr Med Res Opin (2004) 0.85
Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry (1996) 0.84
The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry (2002) 0.82
Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci (1999) 0.79
Defining treatment refractoriness in schizophrenia. Schizophr Bull (1990) 0.79
Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic. Int J Psychiatry Clin Pract (1997) 0.75
Clinical issues associated with maintenance treatment of patients with schizophrenia. Am J Health Syst Pharm (2002) 0.75
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet (2008) 10.52
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet (2008) 10.20
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (2013) 8.20
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet (2008) 4.78
Identifying depression in primary care: a comparison of different methods in a prospective cohort study. BMJ (2003) 3.78
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry (2003) 3.18
What does the PANSS mean? Schizophr Res (2005) 2.86
Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol (2010) 2.74
The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int (2013) 2.73
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry (2008) 2.64
Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry (2002) 2.41
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry (2007) 2.40
Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry (2009) 2.17
Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry (2002) 2.15
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry (2007) 2.05
Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage (2007) 2.03
Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain (2005) 2.03
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry (2005) 1.98
Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. Am J Psychiatry (2011) 1.94
Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry (2007) 1.93
Integration of fMRI and simultaneous EEG: towards a comprehensive understanding of localization and time-course of brain activity in target detection. Neuroimage (2004) 1.84
Prefrontal transcranial direct current stimulation changes connectivity of resting-state networks during fMRI. J Neurosci (2011) 1.81
The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology (2006) 1.79
Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol (2005) 1.75
Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry (2008) 1.75
Factor structure and external validity of the PANSS revisited. Schizophr Res (2005) 1.74
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry (2003) 1.66
Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology (2006) 1.66
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry (2002) 1.63
Depression-related variation in brain morphology over 3 years: effects of stress? Arch Gen Psychiatry (2008) 1.61
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry (2010) 1.61
A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry (2006) 1.57
Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol Psychiatry (2003) 1.55
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci (2008) 1.53
Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage (2006) 1.52
Response and remission criteria in major depression--a validation of current practice. J Psychiatr Res (2010) 1.52
Syndromes and phenomenological subtypes underlying acute mania: a factor analytic study of 576 manic patients. Am J Psychiatry (2002) 1.51
Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract (2012) 1.49
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry (2013) 1.48
Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry (2004) 1.48
Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch Gen Psychiatry (2010) 1.46
Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain (2004) 1.45
Progression of corpus callosum atrophy in Alzheimer disease. Arch Neurol (2002) 1.44
Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. J Clin Psychopharmacol (2003) 1.43
Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. J Clin Psychiatry (2010) 1.41
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Enlargement of the amygdala in patients with a first episode of major depression. Biol Psychiatry (2002) 1.38
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry (2002) 1.38
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev (2014) 1.38
Ethical aspects of publishing. World J Biol Psychiatry (2006) 1.37
Non-linearity and frequency shifts of nuclear magnetic spin-noise. J Magn Reson (2009) 1.37
Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification. Schizophr Bull (2011) 1.36
Public stigma against people with mental illness in the Gilgel Gibe Field Research Center (GGFRC) in Southwest Ethiopia. PLoS One (2013) 1.36
Reduced hippocampal volume correlates with executive dysfunctioning in major depression. J Psychiatry Neurosci (2006) 1.35
Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci (2004) 1.34
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry (2013) 1.34
Use of brief depression screening tools in primary care: consideration of heterogeneity in performance in different patient groups. Gen Hosp Psychiatry (2004) 1.34
Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology (2007) 1.34
Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition. Depress Anxiety (2007) 1.32
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
White matter microstructure underlying default mode network connectivity in the human brain. Neuroimage (2009) 1.29
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry (2002) 1.28
The identification of free-living environmental isolates of amoebae from Bulgaria. Parasitol Res (2004) 1.27
Personality and attempted suicide. Analysis of anger, aggression and impulsivity. J Psychiatr Res (2009) 1.26
Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry (2002) 1.24
An ancestral secretory apparatus in the protozoan parasite Giardia intestinalis. J Biol Chem (2003) 1.23
Is the PANSS used correctly? a systematic review. BMC Psychiatry (2011) 1.22
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res (2010) 1.22
Functional connectivity bias of the orbitofrontal cortex in drug-free patients with major depression. Biol Psychiatry (2010) 1.22
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry (2007) 1.19
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry (2002) 1.19
Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome. Am J Psychiatry (2003) 1.19
Are older antipsychotic drugs obsolete? BMJ (2006) 1.19
Immune System and Schizophrenia. Curr Immunol Rev (2010) 1.18
Signal enhancement in protein NMR using the spin-noise tuning optimum. J Biomol NMR (2010) 1.18
Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. Biol Psychiatry (2004) 1.17
Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families. J Med Genet (2013) 1.16
European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation. Eur Child Adolesc Psychiatry (2011) 1.15
The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers. J Neurosci (2011) 1.14
Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis (2008) 1.13
Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord (2008) 1.13
Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther (2011) 1.12
Childhood stress, serotonin transporter gene and brain structures in major depression. Neuropsychopharmacology (2010) 1.12
Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry (2012) 1.12